<DOC>
	<DOCNO>NCT01527318</DOCNO>
	<brief_summary>Neutral Lipid Storage Disease With Myopath ( NLSDM ) disease cause defect PNPLA2 gene encode ATGL . Patients NLSDM accumulate triglyceride exhibit muscle weakness , cardiac failure hepatosteatosis . Most patient die young age due cardiac failure . Not much know underlying mechanism , though recently discover PPAR activation ATGL-/- mouse impair lead decrease mitochondrial function , lipid accumulation cardiac failure result death young age . Activation PPARs , treatment fibrates rescue phenotype reduce mortality rate mice . These finding may major impact patient NLSDM result translate human . Therefore , investigator would like evaluate beneficial effect fibrate treatment muscle mitochondrial cardiac function patient NLSDM . Patients treated fibrates period 28 week . Baseline measurement perform prior study treatment . Cardiac muscular lipid accumulation , cardiac function , mitochondrial function insulin sensitivity assess baseline measurement .</brief_summary>
	<brief_title>The Effect Fibrate Therapy Two Patients With Neutral Lipid Storage Disease With Myopathy ( NLSDM )</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Ichthyosiform Erythroderma , Congenital</mesh_term>
	<mesh_term>Clofibric Acid</mesh_term>
	<criteria>suffer NLSDM</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>NLSDM</keyword>
	<keyword>Lipid accumulation</keyword>
</DOC>